Skip to main content

Table 3 Metabolites with differing plasma levels among groups

From: The accumulation of plasma acylcarnitines are associated with poor immune recovery in HIV-infected individuals

Name

Pathway

Sub pathway

IR/control

INR/control

INR/IR

VIP

p value

FC

VIP

p value

FC

VIP

p value

FC

Myristoylcarnitine (MC)

Lipid

Fatty Acid Metabolism (Acyl Carnitine)

0.11

9.13E−01

1.06

1.81

4.12E−04

2.11

2.13

1.97E−03

1.99

Laurylcarnitine (LC)

Lipid

Fatty Acid Metabolism (Acyl Carnitine)

0.46

6.93E−01

1.2

1.69

7.29E−04

2.32

2.27

6.16E−03

1.94

Oleoylcarnitine (OC)

Lipid

Fatty Acid Metabolism (Acyl Carnitine)

0.68

4.34E−01

0.91

1.64

1.29E−03

1.74

2.86

5.79E−04

1.9

Stearoylcarnitine (SC)

Lipid

Fatty Acid Metabolism (Acyl Carnitine)

0.71

4.14E−01

0.9

1.71

8.77E−04

1.63

2.80

3.73E−04

1.81

Palmitoylcarnitine (PC)

Lipid

Fatty Acid Metabolism (Acyl Carnitine)

0.09

9.21E−01

1.03

1.64

1.83E−03

1.65

2.54

4.21E−03

1.6

2-hydroxydecanoate

Lipid

Fatty Acid, Monohydroxy

2.07

8.42E−03

0.54

1.62

5.35E−03

0.52

0.48

8.77E−01

0.95

10-nonadecenoate (19:1n9)

Lipid

Long Chain Fatty Acid

1.92

1.53E−02

1.88

2.33

1.00E−05

2.70

1.55

2.76E−02

1.44

Cis-vaccenate (18:1n7)

Lipid

Long Chain Fatty Acid

1.64

4.05E−02

1.36

2.34

4.47E−06

1.90

1.95

6.33E−03

1.4

Oleate (18:1n9)

Lipid

Long Chain Fatty Acid

1.71

2.08E−02

1.56

2.37

1.80E−05

2.13

1.63

3.15E−02

1.37

Margarate (17:0)

Lipid

Long Chain Fatty Acid

2.03

1.24E−02

1.49

2.32

3.87E−06

1.92

1.55

1.73E−02

1.28

Palmitate (16:0)

Lipid

Long Chain Fatty Acid

1.61

5.35E−02

1.38

2.07

5.20E−05

1.76

1.48

2.74E−02

1.27

Stearate (18:0)

Lipid

Long Chain Fatty Acid

1.44

1.14E−01

1.23

2.19

8.39E−06

1.51

1.96

3.19E−03

1.23

10-heptadecenoate (17:1n7)

Lipid

Long Chain Fatty Acid

2.18

3.42E−03

2.16

2.21

7.44E−05

2.62

0.95

2.43E−01

1.21

Palmitoleate (16:1n7)

Lipid

Long Chain Fatty Acid

2.09

2.64E−03

2.35

2.11

1.61E−04

2.73

0.80

3.88E−01

1.16

Dihomo-linoleate (20:2n6)

Lipid

Polyunsaturated Fatty Acid (n3 and n6)

1.68

1.06E−01

1.53

2.11

2.27E−05

2.45

1.63

7.34E−03

1.6

Epiandrosterone sulfate

Lipid

Steroid

2.81

2.58E−05

0.28

1.80

2.07E−04

0.40

0.77

5.41E−01

1.41

Androsterone sulfate

Lipid

Steroid

2.36

4.13E−04

0.27

1.58

1.41E−03

0.36

0.65

7.03E−01

1.35

Andro steroid monosulfate

Lipid

Steroid

2.52

1.26E−03

2.84

1.94

1.02E−03

2.88

0.12

9.48E−01

1.01

  1. Features that meet all following conditions are highlighted using bold text: variable important in projection (VIP) values > 2, p values < 0.05 (FDR < 5%), or fold-change (FC) values > 1.5 or < 0.67
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us